Pharma BD Deal Intelligence
APP gave Fresenius Kabi its US foothold and became a core, still-operating platform, but the deal's own earnout targets were missed and legacy plants drew FDA warning letters before recovering.
Full analysis, sources & comparables →Fresenius chairman Ulf Mark Schneider: "APP is a fast-growing, highly profitable company with a strong management team that has an excellent market position in…
CNBC reported $3.7B base deal with up to $970M CVR ($6/share contingent on 2008-2010 EBITDA targets), characterizing the transaction as Fresenius's largest…
Schneider: "We are pleased to be able to complete this major transaction in a very short time... Through APP, Fresenius Kabi enters the U.S. pharmaceuticals…
Source summaries from our enrichment pipeline; follow links for originals.
All 7 sources with sentiment breakdown →
$23/share cash + CVR up to $970M ($4.6B with CVR; up to $5.6B with assumed debt); injectable generics; closed Sep 10 2008
APP gave Fresenius Kabi its US foothold and became a core, still-operating platform, but the deal's own earnout targets were missed and legacy plants drew FDA warning letters before recovering.
Assessment window: 15yr post-close.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Fresenius SE / Fresenius Kabi / APP Pharmaceuticals, Inc. (this deal) | 2008 | $3.7B | 67 |
| ViroPharma Incorporated / Lev Pharmaceuticals, Inc. | 2008 | $443M | 88 |
| Roche Holding AG / Ventana Medical Systems Inc. | 2008 | $3.4B | 88 |
| Shire plc / Jerini AG | 2008 | $521M | 85 |
| Alkermes plc / Cephalon, Inc. (Vivitrol rights) | 2008 | $27M | 83 |
| Sanofi-Aventis / Symbion Consumer (Primary Health Care) | 2008 | $544M | 71 |
| Takeda Pharmaceutical Company Ltd. / Millennium Pharmaceuticals | 2008 | $8.8B | 68 |
← Browse all deals · How we score deals
More: 2008 deals